Tempus Acquires Personalis for $1.5 Billion in Bid to Control Cancer-Test Market

Tempus AI (TEM) has acquired Personalis (PSNL) for $1.5 billion, gaining full control of the NeXT Personal cancer test that detects minimal residual disease using DNA fragments in blood. Despite Wall Street's strategic approval, Tempus' stock price dropped following the announcement.

By Peace Longe Thu, July 23, 2026 at 3:37 AM GMT+3 6 min read · Yahoo Finance · July 23, 2026, 00:37 UTC

Tempus Acquires Personalis for $1.5 Billion in Bid to Control Cancer-Test Market

Tickers: $PSNL $TEM

Topics: AI biotech cancer diagnostics healthcare

Read the full article at Yahoo Finance

More World news

Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC
Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC